Click on headlines below to download research

Positive Tuzistra trends
Vernalis | 15/03/2017

Investment into addressing barriers to higher Tuzistra XR prescribing is starting to translate into higher prescription (Rx) rates. Mid-way through the…

Advancing towards a commercial portfolio
Vernalis | 05/01/2017

FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of extended…

Investing in the commercial platform
Vernalis | 21/10/2016

Vernalis marked its transition into a commercial-stage speciality pharma company with the September 2015 US launch of Tuzistra XR, the first product from…